China and Boston-based CANbridge Pharmaceuticals Inc, a developer of drugs to treat rare diseases and targeted cancers, has raised $43 million in Series E financing. The lead backer was 3W Fund Management. Other investors in the round included Casdin Capital, Summer Capital, SPDBI and Yaly Capital.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: